Magenta Therapeutics, Inc.
Magenta Therapeutics, Inc. MGTA Peers
See (MGTA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MGTA | $0.70 | -7.74% | 42.4M | -0.61 | -$1.15 | N/A |
| VRTX | $458.49 | -0.29% | 117.7B | -120.34 | -$3.81 | N/A |
| REGN | $545.53 | +0.55% | 57.9B | 13.86 | $39.36 | +0.32% |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $320.52 | -0.00% | 41.8B | -152.63 | -$2.10 | N/A |
| ARGX | $566.14 | +0.27% | 34.6B | 34.56 | $16.38 | N/A |
| BNTX | $108.91 | -1.01% | 26.2B | -28.97 | -$3.76 | N/A |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| RPRX | $35.65 | +0.17% | 20B | 14.55 | $2.45 | +2.99% |
| SMMT | $26.34 | +0.53% | 19.6B | -77.47 | -$0.34 | N/A |
Stock Comparison
MGTA vs VRTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, VRTX has a market cap of 117.7B. Regarding current trading prices, MGTA is priced at $0.70, while VRTX trades at $458.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas VRTX's P/E ratio is -120.34. In terms of profitability, MGTA's ROE is -0.33%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, MGTA is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs REGN Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, REGN has a market cap of 57.9B. Regarding current trading prices, MGTA is priced at $0.70, while REGN trades at $545.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas REGN's P/E ratio is 13.86. In terms of profitability, MGTA's ROE is -0.33%, compared to REGN's ROE of +0.15%. Regarding short-term risk, MGTA is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs SGEN Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, MGTA is priced at $0.70, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas SGEN's P/E ratio is -57.19. In terms of profitability, MGTA's ROE is -0.33%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, MGTA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ALNY Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ALNY has a market cap of 41.8B. Regarding current trading prices, MGTA is priced at $0.70, while ALNY trades at $320.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ALNY's P/E ratio is -152.63. In terms of profitability, MGTA's ROE is -0.33%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, MGTA is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ARGX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ARGX has a market cap of 34.6B. Regarding current trading prices, MGTA is priced at $0.70, while ARGX trades at $566.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ARGX's P/E ratio is 34.56. In terms of profitability, MGTA's ROE is -0.33%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, MGTA is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs BNTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, BNTX has a market cap of 26.2B. Regarding current trading prices, MGTA is priced at $0.70, while BNTX trades at $108.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas BNTX's P/E ratio is -28.97. In terms of profitability, MGTA's ROE is -0.33%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, MGTA is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs BGNE Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, MGTA is priced at $0.70, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas BGNE's P/E ratio is -22.55. In terms of profitability, MGTA's ROE is -0.33%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, MGTA is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RPRX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RPRX has a market cap of 20B. Regarding current trading prices, MGTA is priced at $0.70, while RPRX trades at $35.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RPRX's P/E ratio is 14.55. In terms of profitability, MGTA's ROE is -0.33%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, MGTA is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs SMMT Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, SMMT has a market cap of 19.6B. Regarding current trading prices, MGTA is priced at $0.70, while SMMT trades at $26.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas SMMT's P/E ratio is -77.47. In terms of profitability, MGTA's ROE is -0.33%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, MGTA is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs DNA-WT Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, MGTA is priced at $0.70, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, MGTA's ROE is -0.33%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, MGTA is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs GMAB Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, GMAB has a market cap of 13.4B. Regarding current trading prices, MGTA is priced at $0.70, while GMAB trades at $21.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas GMAB's P/E ratio is 12.76. In terms of profitability, MGTA's ROE is -0.33%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, MGTA is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs UTHR Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, UTHR has a market cap of 13.2B. Regarding current trading prices, MGTA is priced at $0.70, while UTHR trades at $293.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas UTHR's P/E ratio is 11.68. In terms of profitability, MGTA's ROE is -0.33%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, MGTA is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs INCY Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, INCY has a market cap of 13B. Regarding current trading prices, MGTA is priced at $0.70, while INCY trades at $67.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas INCY's P/E ratio is 336.90. In terms of profitability, MGTA's ROE is -0.33%, compared to INCY's ROE of +0.01%. Regarding short-term risk, MGTA is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs KRTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, MGTA is priced at $0.70, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas KRTX's P/E ratio is -28.09. In terms of profitability, MGTA's ROE is -0.33%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, MGTA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs EXEL Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, EXEL has a market cap of 12.1B. Regarding current trading prices, MGTA is priced at $0.70, while EXEL trades at $44.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas EXEL's P/E ratio is 20.21. In terms of profitability, MGTA's ROE is -0.33%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, MGTA is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MRNA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MRNA has a market cap of 12B. Regarding current trading prices, MGTA is priced at $0.70, while MRNA trades at $30.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MRNA's P/E ratio is -3.55. In terms of profitability, MGTA's ROE is -0.33%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, MGTA is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs BMRN Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, BMRN has a market cap of 10.8B. Regarding current trading prices, MGTA is priced at $0.70, while BMRN trades at $56.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas BMRN's P/E ratio is 20.95. In terms of profitability, MGTA's ROE is -0.33%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, MGTA is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ASND Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ASND has a market cap of 10.1B. Regarding current trading prices, MGTA is priced at $0.70, while ASND trades at $168.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ASND's P/E ratio is -24.56. In terms of profitability, MGTA's ROE is -0.33%, compared to ASND's ROE of +1.91%. Regarding short-term risk, MGTA is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RXDX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, MGTA is priced at $0.70, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RXDX's P/E ratio is -56.47. In terms of profitability, MGTA's ROE is -0.33%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, MGTA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs VRNA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, VRNA has a market cap of 8.9B. Regarding current trading prices, MGTA is priced at $0.70, while VRNA trades at $104.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas VRNA's P/E ratio is -52.45. In terms of profitability, MGTA's ROE is -0.33%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, MGTA is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs IMGN Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, MGTA is priced at $0.70, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas IMGN's P/E ratio is -111.55. In terms of profitability, MGTA's ROE is -0.33%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, MGTA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs BBIO Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, BBIO has a market cap of 8.7B. Regarding current trading prices, MGTA is priced at $0.70, while BBIO trades at $45.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas BBIO's P/E ratio is -12.89. In terms of profitability, MGTA's ROE is -0.33%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, MGTA is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs BPMC Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, MGTA is priced at $0.70, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas BPMC's P/E ratio is -51.58. In terms of profitability, MGTA's ROE is -0.33%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, MGTA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CERE Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, MGTA is priced at $0.70, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CERE's P/E ratio is -16.47. In terms of profitability, MGTA's ROE is -0.33%, compared to CERE's ROE of -0.43%. Regarding short-term risk, MGTA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs TECH Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, TECH has a market cap of 7.9B. Regarding current trading prices, MGTA is priced at $0.70, while TECH trades at $50.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas TECH's P/E ratio is 60.57. In terms of profitability, MGTA's ROE is -0.33%, compared to TECH's ROE of +0.06%. Regarding short-term risk, MGTA is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ROIVW Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, MGTA is priced at $0.70, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, MGTA's ROE is -0.33%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, MGTA is more volatile compared to ROIVW. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ROIV Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ROIV has a market cap of 7.8B. Regarding current trading prices, MGTA is priced at $0.70, while ROIV trades at $11.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ROIV's P/E ratio is -15.31. In terms of profitability, MGTA's ROE is -0.33%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, MGTA is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CORT Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CORT has a market cap of 7.4B. Regarding current trading prices, MGTA is priced at $0.70, while CORT trades at $70.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CORT's P/E ratio is 60.97. In terms of profitability, MGTA's ROE is -0.33%, compared to CORT's ROE of +0.20%. Regarding short-term risk, MGTA is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MDGL Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MDGL has a market cap of 7.3B. Regarding current trading prices, MGTA is priced at $0.70, while MDGL trades at $330.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MDGL's P/E ratio is -17.30. In terms of profitability, MGTA's ROE is -0.33%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, MGTA is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RVMD Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RVMD has a market cap of 7.2B. Regarding current trading prices, MGTA is priced at $0.70, while RVMD trades at $38.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RVMD's P/E ratio is -9.58. In terms of profitability, MGTA's ROE is -0.33%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, MGTA is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs HALO Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, HALO has a market cap of 6.9B. Regarding current trading prices, MGTA is priced at $0.70, while HALO trades at $55.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas HALO's P/E ratio is 14.87. In terms of profitability, MGTA's ROE is -0.33%, compared to HALO's ROE of +1.22%. Regarding short-term risk, MGTA is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs JAZZ Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, JAZZ has a market cap of 6.8B. Regarding current trading prices, MGTA is priced at $0.70, while JAZZ trades at $112.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas JAZZ's P/E ratio is 15.31. In terms of profitability, MGTA's ROE is -0.33%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, MGTA is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs IONS Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, IONS has a market cap of 6.6B. Regarding current trading prices, MGTA is priced at $0.70, while IONS trades at $41.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas IONS's P/E ratio is -13.90. In terms of profitability, MGTA's ROE is -0.33%, compared to IONS's ROE of -0.92%. Regarding short-term risk, MGTA is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RETA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, MGTA is priced at $0.70, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RETA's P/E ratio is -66.29. In terms of profitability, MGTA's ROE is -0.33%, compared to RETA's ROE of +0.47%. Regarding short-term risk, MGTA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs AMRN Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, AMRN has a market cap of 6.4B. Regarding current trading prices, MGTA is priced at $0.70, while AMRN trades at $15.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas AMRN's P/E ratio is -3.53. In terms of profitability, MGTA's ROE is -0.33%, compared to AMRN's ROE of -0.17%. Regarding short-term risk, MGTA is more volatile compared to AMRN. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs TGTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, TGTX has a market cap of 5.9B. Regarding current trading prices, MGTA is priced at $0.70, while TGTX trades at $37.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas TGTX's P/E ratio is 149.68. In terms of profitability, MGTA's ROE is -0.33%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, MGTA is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs NUVL Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, NUVL has a market cap of 5.9B. Regarding current trading prices, MGTA is priced at $0.70, while NUVL trades at $82.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas NUVL's P/E ratio is -18.66. In terms of profitability, MGTA's ROE is -0.33%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, MGTA is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CRSP Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, MGTA is priced at $0.70, while CRSP trades at $65.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CRSP's P/E ratio is -14.55. In terms of profitability, MGTA's ROE is -0.33%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, MGTA is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RYTM Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, MGTA is priced at $0.70, while RYTM trades at $88.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RYTM's P/E ratio is -31.65. In terms of profitability, MGTA's ROE is -0.33%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, MGTA is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs TLX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, TLX has a market cap of 5.6B. Regarding current trading prices, MGTA is priced at $0.70, while TLX trades at $16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas TLX's P/E ratio is 184.44. In terms of profitability, MGTA's ROE is -0.33%, compared to TLX's ROE of +0.14%. Regarding short-term risk, MGTA is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ABCM Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, MGTA is priced at $0.70, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, MGTA's ROE is -0.33%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, MGTA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ISEE Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, MGTA is priced at $0.70, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ISEE's P/E ratio is -22.44. In terms of profitability, MGTA's ROE is -0.33%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, MGTA is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs AXSM Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, AXSM has a market cap of 5.4B. Regarding current trading prices, MGTA is priced at $0.70, while AXSM trades at $109.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas AXSM's P/E ratio is -18.65. In terms of profitability, MGTA's ROE is -0.33%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, MGTA is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MRUS Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MRUS has a market cap of 4.6B. Regarding current trading prices, MGTA is priced at $0.70, while MRUS trades at $62.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MRUS's P/E ratio is -14.99. In terms of profitability, MGTA's ROE is -0.33%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, MGTA is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs PCVX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, PCVX has a market cap of 4.6B. Regarding current trading prices, MGTA is priced at $0.70, while PCVX trades at $35.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas PCVX's P/E ratio is -8.93. In terms of profitability, MGTA's ROE is -0.33%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, MGTA is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ALPN Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, MGTA is priced at $0.70, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ALPN's P/E ratio is -101.52. In terms of profitability, MGTA's ROE is -0.33%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, MGTA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CYTK Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CYTK has a market cap of 4.4B. Regarding current trading prices, MGTA is priced at $0.70, while CYTK trades at $36.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CYTK's P/E ratio is -6.99. In terms of profitability, MGTA's ROE is -0.33%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, MGTA is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ALKS Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, MGTA is priced at $0.70, while ALKS trades at $26.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ALKS's P/E ratio is 12.70. In terms of profitability, MGTA's ROE is -0.33%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, MGTA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for MGTA.
MGTA vs SLNO Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, SLNO has a market cap of 4.4B. Regarding current trading prices, MGTA is priced at $0.70, while SLNO trades at $86.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas SLNO's P/E ratio is -18.35. In terms of profitability, MGTA's ROE is -0.33%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, MGTA is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs KRYS Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, KRYS has a market cap of 4.3B. Regarding current trading prices, MGTA is priced at $0.70, while KRYS trades at $148.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas KRYS's P/E ratio is 35.60. In terms of profitability, MGTA's ROE is -0.33%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, MGTA is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs OPT Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, MGTA is priced at $0.70, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas OPT's P/E ratio is -1.52. In terms of profitability, MGTA's ROE is -0.33%, compared to OPT's ROE of +2.60%. Regarding short-term risk, MGTA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MTSR Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MTSR has a market cap of 4.2B. Regarding current trading prices, MGTA is priced at $0.70, while MTSR trades at $39.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MTSR's P/E ratio is -15.71. In terms of profitability, MGTA's ROE is -0.33%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, MGTA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for MGTA.
MGTA vs MRTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, MGTA is priced at $0.70, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MRTX's P/E ratio is -4.82. In terms of profitability, MGTA's ROE is -0.33%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, MGTA is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RNA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RNA has a market cap of 4.1B. Regarding current trading prices, MGTA is priced at $0.70, while RNA trades at $34.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RNA's P/E ratio is -11.34. In terms of profitability, MGTA's ROE is -0.33%, compared to RNA's ROE of -0.27%. Regarding short-term risk, MGTA is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs AKRO Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, AKRO has a market cap of 4.1B. Regarding current trading prices, MGTA is priced at $0.70, while AKRO trades at $51.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas AKRO's P/E ratio is -13.70. In terms of profitability, MGTA's ROE is -0.33%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, MGTA is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ADMA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ADMA has a market cap of 4.1B. Regarding current trading prices, MGTA is priced at $0.70, while ADMA trades at $17.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ADMA's P/E ratio is 20.39. In terms of profitability, MGTA's ROE is -0.33%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, MGTA is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs SRRK Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, SRRK has a market cap of 3.9B. Regarding current trading prices, MGTA is priced at $0.70, while SRRK trades at $41.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas SRRK's P/E ratio is -16.13. In terms of profitability, MGTA's ROE is -0.33%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, MGTA is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs LEGN Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, LEGN has a market cap of 3.9B. Regarding current trading prices, MGTA is priced at $0.70, while LEGN trades at $42.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas LEGN's P/E ratio is -35.79. In terms of profitability, MGTA's ROE is -0.33%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, MGTA is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ZLAB Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ZLAB has a market cap of 3.8B. Regarding current trading prices, MGTA is priced at $0.70, while ZLAB trades at $34.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ZLAB's P/E ratio is -13.86. In terms of profitability, MGTA's ROE is -0.33%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, MGTA is more volatile compared to ZLAB. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ACLX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ACLX has a market cap of 3.8B. Regarding current trading prices, MGTA is priced at $0.70, while ACLX trades at $69.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ACLX's P/E ratio is -23.21. In terms of profitability, MGTA's ROE is -0.33%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, MGTA is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs PTCT Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, PTCT has a market cap of 3.8B. Regarding current trading prices, MGTA is priced at $0.70, while PTCT trades at $47.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas PTCT's P/E ratio is 7.35. In terms of profitability, MGTA's ROE is -0.33%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, MGTA is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RYZB Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, MGTA is priced at $0.70, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RYZB's P/E ratio is -57.86. In terms of profitability, MGTA's ROE is -0.33%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, MGTA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs ACAD Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, ACAD has a market cap of 3.7B. Regarding current trading prices, MGTA is priced at $0.70, while ACAD trades at $22.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas ACAD's P/E ratio is 16.26. In terms of profitability, MGTA's ROE is -0.33%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, MGTA is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CBAY Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, MGTA is priced at $0.70, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CBAY's P/E ratio is -32.81. In terms of profitability, MGTA's ROE is -0.33%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, MGTA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs VKTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, VKTX has a market cap of 3.6B. Regarding current trading prices, MGTA is priced at $0.70, while VKTX trades at $31.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas VKTX's P/E ratio is -27.53. In terms of profitability, MGTA's ROE is -0.33%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, MGTA is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs SWTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, MGTA is priced at $0.70, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas SWTX's P/E ratio is -13.78. In terms of profitability, MGTA's ROE is -0.33%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, MGTA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs AAPG Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, MGTA is priced at $0.70, while AAPG trades at $39.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas AAPG's P/E ratio is -52.95. In terms of profitability, MGTA's ROE is -0.33%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, MGTA is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs PTGX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, PTGX has a market cap of 3.4B. Regarding current trading prices, MGTA is priced at $0.70, while PTGX trades at $55.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas PTGX's P/E ratio is 70.79. In terms of profitability, MGTA's ROE is -0.33%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, MGTA is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MLTX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MLTX has a market cap of 3.4B. Regarding current trading prices, MGTA is priced at $0.70, while MLTX trades at $53.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MLTX's P/E ratio is -23.29. In terms of profitability, MGTA's ROE is -0.33%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, MGTA is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs NAMSW Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, NAMSW has a market cap of 3.2B. Regarding current trading prices, MGTA is priced at $0.70, while NAMSW trades at $11.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas NAMSW's P/E ratio is N/A. In terms of profitability, MGTA's ROE is -0.33%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, MGTA is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs KYMR Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, KYMR has a market cap of 3.2B. Regarding current trading prices, MGTA is priced at $0.70, while KYMR trades at $45.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas KYMR's P/E ratio is -14.51. In terms of profitability, MGTA's ROE is -0.33%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, MGTA is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs IMVT Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, IMVT has a market cap of 3B. Regarding current trading prices, MGTA is priced at $0.70, while IMVT trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas IMVT's P/E ratio is -6.48. In terms of profitability, MGTA's ROE is -0.33%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, MGTA is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CRNX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CRNX has a market cap of 2.9B. Regarding current trading prices, MGTA is priced at $0.70, while CRNX trades at $30.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CRNX's P/E ratio is -8.14. In terms of profitability, MGTA's ROE is -0.33%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, MGTA is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MORF Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, MGTA is priced at $0.70, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MORF's P/E ratio is -14.88. In terms of profitability, MGTA's ROE is -0.33%, compared to MORF's ROE of -0.22%. Regarding short-term risk, MGTA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MOR Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, MGTA is priced at $0.70, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MOR's P/E ratio is -12.64. In terms of profitability, MGTA's ROE is -0.33%, compared to MOR's ROE of -1.84%. Regarding short-term risk, MGTA is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs LGND Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, LGND has a market cap of 2.7B. Regarding current trading prices, MGTA is priced at $0.70, while LGND trades at $141.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas LGND's P/E ratio is -19.36. In terms of profitability, MGTA's ROE is -0.33%, compared to LGND's ROE of -0.16%. Regarding short-term risk, MGTA is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs KDNY Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, MGTA is priced at $0.70, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas KDNY's P/E ratio is -12.47. In terms of profitability, MGTA's ROE is -0.33%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, MGTA is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MYOV Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, MGTA is priced at $0.70, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MYOV's P/E ratio is -14.05. In terms of profitability, MGTA's ROE is -0.33%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, MGTA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs MIRM Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, MGTA is priced at $0.70, while MIRM trades at $51.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas MIRM's P/E ratio is -32.27. In terms of profitability, MGTA's ROE is -0.33%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, MGTA is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CPRX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, MGTA is priced at $0.70, while CPRX trades at $21.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CPRX's P/E ratio is 13.38. In terms of profitability, MGTA's ROE is -0.33%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, MGTA is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RXRX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RXRX has a market cap of 2.6B. Regarding current trading prices, MGTA is priced at $0.70, while RXRX trades at $6.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RXRX's P/E ratio is -3.81. In terms of profitability, MGTA's ROE is -0.33%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, MGTA is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for MGTA.
MGTA vs NAMS Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, NAMS has a market cap of 2.5B. Regarding current trading prices, MGTA is priced at $0.70, while NAMS trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas NAMS's P/E ratio is -12.26. In terms of profitability, MGTA's ROE is -0.33%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, MGTA is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs IMRA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, IMRA has a market cap of 2.5B. Regarding current trading prices, MGTA is priced at $0.70, while IMRA trades at $50.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas IMRA's P/E ratio is N/A. In terms of profitability, MGTA's ROE is -0.33%, compared to IMRA's ROE of -0.41%. Regarding short-term risk, MGTA is more volatile compared to IMRA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs RARE Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, RARE has a market cap of 2.5B. Regarding current trading prices, MGTA is priced at $0.70, while RARE trades at $26.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas RARE's P/E ratio is -4.53. In terms of profitability, MGTA's ROE is -0.33%, compared to RARE's ROE of -1.86%. Regarding short-term risk, MGTA is more volatile compared to RARE. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs APLS Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, APLS has a market cap of 2.4B. Regarding current trading prices, MGTA is priced at $0.70, while APLS trades at $19.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas APLS's P/E ratio is -10.71. In terms of profitability, MGTA's ROE is -0.33%, compared to APLS's ROE of -1.00%. Regarding short-term risk, MGTA is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs XENE Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, XENE has a market cap of 2.4B. Regarding current trading prices, MGTA is priced at $0.70, while XENE trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas XENE's P/E ratio is -9.78. In terms of profitability, MGTA's ROE is -0.33%, compared to XENE's ROE of -0.32%. Regarding short-term risk, MGTA is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs PRVB Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, MGTA is priced at $0.70, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas PRVB's P/E ratio is -16.43. In terms of profitability, MGTA's ROE is -0.33%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, MGTA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs IBRX Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, IBRX has a market cap of 2.4B. Regarding current trading prices, MGTA is priced at $0.70, while IBRX trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas IBRX's P/E ratio is -4.70. In terms of profitability, MGTA's ROE is -0.33%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, MGTA is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs LBPH Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, MGTA is priced at $0.70, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas LBPH's P/E ratio is -26.66. In terms of profitability, MGTA's ROE is -0.33%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, MGTA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs APGE Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, MGTA is priced at $0.70, while APGE trades at $39.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas APGE's P/E ratio is -10.83. In terms of profitability, MGTA's ROE is -0.33%, compared to APGE's ROE of -0.19%. Regarding short-term risk, MGTA is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs AGIO Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, AGIO has a market cap of 2.3B. Regarding current trading prices, MGTA is priced at $0.70, while AGIO trades at $39.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas AGIO's P/E ratio is 3.46. In terms of profitability, MGTA's ROE is -0.33%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, MGTA is more volatile compared to AGIO. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs DICE Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, MGTA is priced at $0.70, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas DICE's P/E ratio is -21.91. In terms of profitability, MGTA's ROE is -0.33%, compared to DICE's ROE of +0.56%. Regarding short-term risk, MGTA is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CALT Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, MGTA is priced at $0.70, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CALT's P/E ratio is -22.73. In terms of profitability, MGTA's ROE is -0.33%, compared to CALT's ROE of -1.67%. Regarding short-term risk, MGTA is more volatile compared to CALT. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CNTA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CNTA has a market cap of 2.1B. Regarding current trading prices, MGTA is priced at $0.70, while CNTA trades at $16.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CNTA's P/E ratio is -8.54. In terms of profitability, MGTA's ROE is -0.33%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, MGTA is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs GLPG Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, GLPG has a market cap of 2.1B. Regarding current trading prices, MGTA is priced at $0.70, while GLPG trades at $32.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas GLPG's P/E ratio is -10.04. In terms of profitability, MGTA's ROE is -0.33%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, MGTA is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs BEAM Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, BEAM has a market cap of 2.1B. Regarding current trading prices, MGTA is priced at $0.70, while BEAM trades at $21.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas BEAM's P/E ratio is -4.56. In terms of profitability, MGTA's ROE is -0.33%, compared to BEAM's ROE of -0.44%. Regarding short-term risk, MGTA is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs KNSA Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, KNSA has a market cap of 2.1B. Regarding current trading prices, MGTA is priced at $0.70, while KNSA trades at $28.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas KNSA's P/E ratio is -118.42. In terms of profitability, MGTA's ROE is -0.33%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, MGTA is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs IRON Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, MGTA is priced at $0.70, while IRON trades at $59.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas IRON's P/E ratio is -15.26. In terms of profitability, MGTA's ROE is -0.33%, compared to IRON's ROE of -0.23%. Regarding short-term risk, MGTA is more volatile compared to IRON. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.
MGTA vs CGON Comparison
MGTA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MGTA stands at 42.4M. In comparison, CGON has a market cap of 2.1B. Regarding current trading prices, MGTA is priced at $0.70, while CGON trades at $26.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MGTA currently has a P/E ratio of -0.61, whereas CGON's P/E ratio is -18.18. In terms of profitability, MGTA's ROE is -0.33%, compared to CGON's ROE of -0.17%. Regarding short-term risk, MGTA is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for MGTA.